Explore UAB

A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults with Neurofibromatosis Type 1


To evaluate the efficacy of Poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR) within the first 48 weeks (12 cycles) of therapy


Poly-ICLC is a synthetic drug that is being studied in the treatment of cancer and for its ability to stimulate the immune system. Previous trials of Poly-ICLC in both adults and children have suggested a possible beneficial effect in adults and children with newly diagnosed or recurrent brain tumors.


This study is open to participants less than 22 year of age who have Neurofibromatosis Type 1 with low grade glioma (WHO Grade 1 and 2) and have had at least one prior medical treatment for the target low grade glioma. A full list of criteria can be obtained by contacting one of the study sites and/or checking clinicaltrials.gov.


Study participants will receive Poly-ICLC administered by intramuscular injection twice weekly for approximately 2 years (24 cycles of therapy). Clinical response is assessed by MRI every 3 months.


  • Dolly Aguilera, MD (Chair)
  • David Wolf, MD (Co-Chair)
  • Miriam Bornhorst, MD (Co-Chair)


The Poly-ICLC study is currently enrolling eligible participants.